You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
HTG Molecular will provide Firalis with technology and components to support its commercialization of a rheumatoid arthritis theranostic assay.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Biogen will now be able to supply Lisa Tracker monitoring kits in the competitive tenders in which it participates in France and other parts of Europe.
The 18-month study will assess whether Vectra DA enables better patient outcomes and reduces costs compared to conventional approaches.
The partners will use Immunovia's antibody array platform for the discovery of diagnostic biomarkers associated with four autoimmune diseases.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
Compiling results from six previous studies, the analysis found Vectra DA scores are associated with worsening disease but didn't address clinical utility.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.